

Ravi B Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/18057/publications.pdf>

Version: 2024-02-01

65
papers

1,209
citations

535685

17
h-index

488211

31
g-index

65
all docs

65
docs citations

65
times ranked

2228
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Pericardial Fat with Cardiac Structure, Function, and Mechanics: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 579-587.e5.	1.2	2
2	Collagen homeostasis of the left atrium: an emerging treatment target to prevent heart failure?. <i>European Journal of Heart Failure</i> , 2022, 24, 332-334.	2.9	2
3	Genetic variation in sodium glucose co-transporter 1 and cardiac structure and function at middle age. <i>ESC Heart Failure</i> , 2022, 9, 1496-1501.	1.4	1
4	Inclusion Criteria for HFpEF Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity. <i>Journal of Cardiac Failure</i> , 2022, , .	0.7	2
5	Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate. <i>European Journal of Heart Failure</i> , 2022, 24, 867-870.	2.9	3
6	Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , 2022, 45, 1549-1557.	4.3	6
7	Depressive Symptoms Are Associated with Reduced Cardiac Function Among Hispanics: Results from the PREVENCIÓN Study. <i>International Journal of Behavioral Medicine</i> , 2021, 28, 531-539.	0.8	2
8	Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 68-77.	3.0	12
9	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 309-317.	0.7	9
10	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 354.	3.0	15
11	Association of proteinuria with incident atrial fibrillation in the general Japanese population. <i>Journal of Cardiology</i> , 2021, 77, 100-105.	0.8	7
12	First-degree atrioventricular block is significantly associated with incident atrial fibrillation in the population predominantly including participants aged ≥60 years. <i>Heart and Vessels</i> , 2021, 36, 1401-1409.	0.5	4
13	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. <i>Scientific Reports</i> , 2021, 11, 4885.	1.6	31
14	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021, 143, 949-958.	1.6	15
15	Left Atrial Myopathy in Atrial Fibrillation and Heart Failure: Clinical Implications, Mechanisms, and Therapeutic Targets. <i>Current Heart Failure Reports</i> , 2021, 18, 85-98.	1.3	19
16	Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 455-464.	1.2	5
17	Associations of Cardiac Mechanics With Exercise Capacity. <i>Journal of the American College of Cardiology</i> , 2021, 78, 245-257.	1.2	13
18	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	1.2	90

#	ARTICLE	IF	CITATIONS
19	The splanchnic reservoir: an oasis for blood volume in heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2021, 23, 1144-1146.	2.9	1
20	Atrial fibrillation and atrial cardiomyopathies. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2845-2853.	0.8	5
21	Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life. <i>JAMA Cardiology</i> , 2020, 5, 184.	3.0	18
22	Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension. <i>ESC Heart Failure</i> , 2020, 7, 254-264.	1.4	39
23	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 270-275.	0.7	10
24	Postâ€ discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2020, 22, 164-167.	2.9	3
25	Addressing Comorbidities in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 441-456.	1.0	13
26	Circulating Vascular Cell Adhesion Moleculeâ€1 and Incident Heart Failure: The Multiâ€Ethnic Study of Atherosclerosis (MESA). <i>Journal of the American Heart Association</i> , 2020, 9, e019390.	1.6	30
27	Fibroblast Growth Factor 23 and Long-Term Cardiac Function. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e011925.	1.3	21
28	Cellular Adhesion Molecules in YoungâAdulthood and Cardiac Function in LaterâLife. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2156-2165.	1.2	33
29	Therapeutic Targeting of Left Atrial Myopathy in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 497.	3.0	38
30	Embarking upon atrial fibrillation management in heart failure with preserved ejection fraction: Charting a course. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2284-2287.	0.8	1
31	Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 233-242.	0.7	9
32	Characterization of cardiac mechanics and incident atrial fibrillation in participants of the Cardiovascular Health Study. <i>JCI Insight</i> , 2020, 5, .	2.3	22
33	Association of the H₂FPEF Risk Score with Recurrence of Atrial Fibrillation Following Pulmonary Vein Isolation. <i>Journal of Atrial Fibrillation</i> , 2020, 12, 2295.	0.5	4
34	Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1267-1269.	2.9	3
35	Implications of Specialist Density for Diabetes Care in the United States. <i>JAMA Cardiology</i> , 2019, 4, 1174.	3.0	18
36	Sudden Cardiac Death Risk Distribution in the United States Population (from NHANES, 2005 to 2012). <i>American Journal of Cardiology</i> , 2019, 123, 1249-1254.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598.	1.2	38
38	Open Access Publishing and Subsequent Citations Among Articles in Major Cardiovascular Journals. <i>American Journal of Medicine</i> , 2019, 132, 1103-1105.	0.6	15
39	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1660-1666.	0.7	5
40	Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 235-237.	2.9	10
41	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 47-55.	1.9	10
42	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 41-63.	4.2	23
43	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018, 137, 938-947.	1.6	17
44	Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 875-877.	0.6	1
45	Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals. <i>JAMA Cardiology</i> , 2018, 3, 1249.	3.0	31
46	Epirubicin and long-term heart failure risk in breast cancer survivors. <i>European Journal of Heart Failure</i> , 2018, 20, 1454-1456.	2.9	4
47	Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. <i>European Journal of Heart Failure</i> , 2018, 20, 1379-1381.	2.9	9
48	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 944-954.	1.3	5
49	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq1 1 0.784314rgBT /Overlock	0.7	6
50	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303.	0.8	9
51	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	1.2	193
52	Integrating electronic health records into the study of heart failure: promises and pitfalls. <i>European Journal of Heart Failure</i> , 2017, 19, 1128-1130.	2.9	8
53	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. <i>Current Heart Failure Reports</i> , 2017, 14, 217-222.	1.3	13
54	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. , 2017, 176, 32-39.		54

#	ARTICLE	IF	CITATIONS
55	Hemoglobin A1c levels and risk of sudden cardiac death: A nested case-control study. <i>Heart Rhythm</i> , 2017, 14, 72-78.	0.3	14
56	Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. <i>European Journal of Heart Failure</i> , 2016, 18, 1190-1192.	2.9	6
57	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016, 214, 16-18.	0.8	2
58	Stroke prevention in heart failure and sinus rhythm: where do we go from here?. <i>European Journal of Heart Failure</i> , 2016, 18, 1267-1269.	2.9	1
59	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , 2016, 21, 455-462.	1.7	26
60	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016, 117, 1845-1850.	0.7	11
61	Clinical Features of Heart Failure and Acute Coronary Syndromes. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 15-30.	0.7	4
62	Identifying Early Changes in Myocardial Microstructure in Hypertensive Heart Disease. <i>PLoS ONE</i> , 2014, 9, e97424.	1.1	16
63	Look Before You Leap (Treat): Severely Low High-density Lipoprotein Cholesterol. <i>American Journal of Medicine</i> , 2013, 126, e1-e2.	0.6	0
64	Clinical Characteristics and Prevalence of Early Repolarization Associated With Ventricular Arrhythmias Following Acute ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2012, 110, 615-620.	0.7	48
65	Early Repolarization Associated With Ventricular Arrhythmias in Patients With Chronic Coronary Artery Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 489-495.	2.1	114